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Background: Trichorhinophalangeal syndrome (TRPS) is a rare autosomal dominant genetic disorder characterised
by distinctive craniofacial and skeletal abnormalities. TRPS is generally associated with mutations in the TRPS1 gene
at 8q23.3 or microdeletions of the 8q23.3-q24.11 region. However, three deletions affecting the same chromosome
region and a familial translocation t(8;13) co-segregating with TRPS, which do not encompass or disrupt the
TRPS1 gene, have been reported. A deregulated expression of TRPS1 has been hypothesised as cause of the TRPS
phenotype of these patients.
Case presentation: We report the clinical and molecular characterisation of a 57-year-old Caucasian woman
carrying the t(2;8)(p16.1;q23.3) de novo balanced translocation. The proband presented with peculiar clinical
features (severe craniofacial dysmorphism, alopecia universalis, severe scoliosis, mitral valve prolapse, mild mental
impairment and normal growth parameters) that partially overlap with TRPS I. Mutational and array CGH analyses
ruled out any genetic defect affecting TRPS1 or genomic alteration at the translocation breakpoint or elsewhere
in the genome. Breakpoint mapping excluded disruption of TRPS1, and revealed that the chromosome 8q23.3
breakpoint was located within the IVS10 of the long intergenic non-coding RNA LINC00536, at approximately
300 kb from the TRPS1 5’ end. Conversely, the 2p16.1 breakpoint mapped within a LINE sequence, in a region
that lacks transcriptional regulatory elements. As a result of the translocation, nucleotide base pair additions and
deletions were detected at both breakpoint junction fragments, and an evolutionarily conserved VISTA enhancer
element from 2p16.1 was relocated at approximately 325 kb from the TRPS1 promoter.
Conclusions: We suggest that the disruption of the genomic architecture of cis regulatory elements downstream
the TRPS1 5′ region, combined with the translocation of a novel enhancer element nearby TRPS1, might be the
pathogenetic mechanism underpinning the proband’s phenotype. The clinical and genetic characterisation of the
present subject allowed us to make a genetic diagnosis in the context of a known syndrome, contributing to a
better comprehension of the complex transcriptional regulation of TRPS1 and TRPS ethiopathogenesis.
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Trichorhinophalangeal syndrome (TRPS) is a complex
malformative disorder with autosomal dominant inherit-
ance that is characterised by distinctive craniofacial and
skeletal abnormalities [1]. TRPS patients generally present
slow-growing and sparse scalp hair, medially thick and
laterally thin eyebrows, a bulbous pear-shaped nose, a long
flat philtrum, a thin upper vermilion border, large pro-
truding ears [2], and bone abnormalities including mild to
severe brachydactyly, cone-shaped epiphyses, hip dysplasia
and short stature [2]. Malformations of inner organs have
also been reported [3].
Three TRPS types can be distinguished at the clinical
and molecular levels: TRPS I, II and III [1]. TRPS I
(OMIM 190350) occurs as a consequence of inactivating
mutations or chromosomal abnormalities that delete or
disrupt the TRPS1 gene [1,4-7]. TRPS II (OMIM 150230)
is a contiguous gene syndrome caused by heterozygous
deletions in 8q23.3–q24.11 involving the TRPS1 and EXT1
genes [8,9]. TRPS II is phenotypically distinguished from
TRPS I by the presence of multiple cartilaginous exostoses
and other less frequent features, such as intellectual dis-
ability, lax skin and a tendency toward bone fractures.
Finally, TRPS III (OMIM 190351) is the result of mis-
sense mutations in the region of TRPS1 that encodes a
GATA-type zinc finger domain [2,6,10]. The primary
clinical difference between TRPS I and TRPS III is in
the severity of the skeletal abnormalities, especially bra-
chydactyly and short stature [11].
The high dosage sensitivity of the TRPS1 gene is under-
scored by mosaicism in some reported cases [9]. More-
over, a perturbation of TRPS1 expression was previously
hypothesised as causative in three TRPS II patients. These
patients carried deletions at chromosome 8q24, which
encompassed only the EXT1 gene. In two of them, the
proximal breakpoint was established and occurred at ap-
proximately 99.3 and 600–800 kb, respectively, from the
TRPS1 5′ end [12-14]. Furthermore, a familial transloca-
tion t(8;13)(q23.3;q21.31), which did not disrupt TRPS1
and co-segregated with TRPS I, was recently described
[15]. In this case, the translocation resulted in the disrup-
tion of a transposon type I element, located at 87 kb from
the TRPS1 5′ end, and in the simultaneous relocation of a
non-coding conserved VISTA enhancer element from
13q21.31 within the TRPS1 5′ region, apparently leading
to an increase in TRPS1 gene expression in the transloca-
tion carriers [15].
In the current study, we report on a proband with a t
(2;8)(p16.1;q23.3) de novo reciprocal chromosomal trans-
location who exhibits peculiar clinical features which
mainly overlap with TRPS I. This is the second case in
which a translocation breakpoint (bkp) does not interrupt
the TRPS1 gene and is not associated with its deletion.
As in the previous report, identification of the bkpsat nucleotide resolution suggests that, first the disrup-
tion and possibly the removal of TRPS1 cis regulatory
elements and then the relocation of a conserved VISTA
enhancer element nearby the TRPS1 5′ end, may be the
cause of the proband’s unusual phenotype.
Case presentation
Clinical report
The proband is a 57-year-old Caucasian woman, born
after an uncomplicated pregnancy to non-consanguineous
healthy parents. The auxological parameters at birth were
on the 50th percentile.
During childhood and adolescence growth was normal
until a final height of 165 cm was reached, consistent with
the proband’s midparental target height (167 cm). Psycho-
motor development was normal. Menarche occurred at
14 years, and menses have always been regular until
menopause, which occurred at 45 years after surgery for
hysterectomy. The proband showed no hair growth from
early childhood and this rapidly progressed to alopecia
universalis (i.e., absence of eyebrows and, after puberty,
absence of pubic and axillary hair).
After the age of 15 years, the proband experienced
several episodes of falls without loss of consciousness,
but all neurological examinations performed (MRI, EMG
and EEG) appeared normal. Echocardiogram revealed
prolapse of both mitral valve leaflets and slight mitral
regurgitation. After regular cardiologic follow-up, valve
replacement was performed at the age of 45 years. Intra-
operative findings revealed thickened mitral valve leaflets
with the appearance of myxomatous degeneration, as
confirmed by histological analysis. In the same year, the
proband had a hysterectomy due to the presence of
several fibroids, but the ovaries were preserved. Before
surgery, she also suffered from a severe uterine prolapse.
We saw the proband for the first time at the age of 51,
as she was referred to an endocrinology outpatient clinic
because of hyperparathyroidism related to vitamin D
deficiency. Endocrinology and genetic analyses were per-
formed, with the aim of confirming a diagnosis of familial
hyperparathyroidism based on the primary hyperparathyr-
oidism of her mother. No germ-line mutations of the mul-
tiple endocrine neoplasia I (MEN1) gene were observed.
Consequently, a diagnosis of tertiary hyperparathyroidism
resulting from autonomous activity of the parathyroid
glands, related to long-standing vitamin D deficiency, was
raised. In addition, high levels of glycosylated haemoglobin
(8%; reference range 4.5–6.5%) were observed, and the
proband underwent metformin therapy. Bone mineral
density evaluated by dual energy X-ray absorptiometry
(Hologic) revealed vertebral and femoral osteoporosis
(lumbar spine T score of −3.5 and femoral neck T score
of −2.5), which was considered secondary to the endo-
crinological problems. There was no history of urolithiasis
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normal, and only a nephroptosis of the right kidney was
apparent. In addition, the proband’s mother referred a very
high pain threshold in her daughter, who, for example,
never required analgesia after surgery. The proband ex-
hibited an important visual impairment characterised by
severe astigmatism, cataracts and photophobia.
Physical examination revealed several craniofacial
anomalies suggestive of a genetic disease: universal alope-
cia, deep-set eyes, bulbous pear-shaped nose, elongated
philtrum, thin upper lip, high-arched palate, and large and
prominent ears. The proband referred that her craniofacial
dysmorphisms had been partially corrected by plastic sur-
gery at the age of 43 years, particularly in the periorbital,
maxillary, and mandibular areas, suggesting the presence
of severe facial bone anomalies. However, we cannot con-
firm these information as she would not grant permission
for us to see pre-surgery facial photographs and the sur-
gery report was not available. Finally, she showed bilateral
valgi and flat feet, and an anxious and obsessive psy-
chological attitude. Cognitive function was not formally
evaluated.
The observed clinical findings suggested a diagnosis of
Trichorhinophalangeal syndrome. Therefore, a radio-
logical study of the skeleton was performed; this revealed
hypoplastic mandibular condyles and severe scoliosis. No
abnormalities were observed in hands (Additional file 1:
Figure S1), arms, legs and pelvis. At age 56 an infiltrating
ductal carcinoma, sized 11 cm, was identified in the right
breast, and was subsequently removed by mastectomy.
Histological examination characterised the cancer as
oestrogen-negative, and the proband is currently undergo-
ing chemotherapy.
The proband does not accept the genetic basis for her
condition, and denied permission to release her photos
for publication.
Methods
Cytogenetic analysis
Conventional cytogenetic analysis was performed on the
proband and her healthy parents on QFQ-banded meta-
phases prepared from peripheral blood lymphocytes using
standard procedures. The karyotypes were described in
accordance with ISCN (2009) [16].
High-resolution array comparative genomic hybridisation
(CGH) analysis
Genomic DNA was extracted from whole blood using
the GenElute Blood Genomic DNA kit (Sigma-Aldrich,
St. Louis, MO). Array CGH analysis was performed
using the Human Genome CGH Microarray Kit 244 K
(Agilent Technologies, Palo Alto, CA). From both test
and normal reference samples, 3 μg of DNA were proc-
essed according to the manufacturer’s instructions. Imageswere captured using the Agilent Feature Extraction 9.1
software and chromosomal profile was acquired using the
ADM-2 algorithm provided by DNA Analytics software
(v4.0) (Agilent Technologies).
Fluorescence in situ hybridisation (FISH) analysis
FISH mapping of the bkps was performed using BAC
clones, targeting the chromosomal bkp regions 2p16.1-
p15 and 8q23.3-q24.1, as probes. The clones were
provided by Invitrogen ltd (Carlsbad, CA, USA), and
selected by consulting the UCSC Genome Browser
Database (University of California Santa Cruz, reference
genome assembly GRCh37/hg19) [17]. All BAC clone
DNAs were labelled by nick-translation with Cy3-dUTP
(GE Healthcare, Little Chalfont, Buckinghamshire, UK)
and the FISH protocol described by Lichter and Cremer
[18] was followed, with minor modifications.
The 2p breakpoint was further narrowed down by
means of three contiguous overlapping 15-kb long-range
polymerase chain reaction (LR-PCR) products as probes
(LRP I, II, III). The fragments were amplified by LR-PCR
using the TaKaRa LA Taq™ kit (Takara Bio Inc., Shiga,
Japan) using approximately 100 ng of BAC clone CTD-
2562H20 as template, and then labelled by random prim-
ing (Prime-It Fluor Fluorescence labelling kit, Stratagene,
Amsterdam, Netherlands). The primer pairs are shown in
Additional file 2: Table S1.
Amplification of the junction fragments
To localize the breakpoints at nucleotide level, sequence-
specific LR-PCR was carried out. Oligonucleotides and
amplification conditions used to amplify the derivative
chromosome der(2) and der(8) junction fragments are
shown in Table 1 and Additional file 3: Table S2. LR-PCRs
were performed using the TaKaRa LA Taq™ kit (Takara
Bio Inc.), and the resulting junction fragments were
sequenced using the Big Dye® Terminator v.3.1 Cycle
Sequencing kit (Applied Biosystems, Foster City, CA).
Sequences were then aligned to the human reference
genome sequence (human genome assembly GRCh37/
hg19), analysed with the ChromasPro 1.5 software (Tech-
nelysium Pty Ltd., Tewantin QLD, Australia), and submit-
ted to GenBank (http://www.ncbi.nlm.nih.gov/WebSub).
In-silico analysis of bkp regions was performed by consult-
ing the UCSC Genome Browser and the VISTA Enhancer
Browser Database [19].
Mutation screening
The entire coding sequence, intron-exon junctions and
untranslated exons of the TRPS1 gene (RefSeq Accession:
NM_014112.4) were amplified for mutation screening
by PCR using the AmpliTaq Gold® kit (Applied Bio-
systems). The primer pairs and amplification conditions
Table 1 Primers used for amplification of der(2) and der(8) junction fragments
Fragment Designation Primer sequence (5′→3′) Primer localizationa Annealing T(°C) PCR size (bp)
Der(8) junction fragment AF130342-3FW CCTTCTAGAGCAAATTCTTTTAGACCTTGA chr8:116,981,340-116,981,369 62.4 632
AC007131-5FW CTCATGGTGTAGAATAGAAGCAGCAAGT chr2:59,567,411-59,567,438
Der(2) junction fragment AF130342-1RW GTTGACATCAGGACTTCAGGTAAATGAA chr8:116,981,900-116,981,927 61.4 701
AC007131-4RW AATTTCTCCTTTATTCCTCTCCCCTTTC chr2:59,568,122-59,568,149
aPrimer physical localization is based on GRCh37/hg19 human genome assembly.
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was performed as described before.
Results
Standard cytogenetic analysis revealed in the proband a
de novo apparently balanced reciprocal chromosome
translocation between the short arm of chromosome 2
and the long arm of chromosome 8 [t(2;8)(p15;q24.1)].
The proband’s parents had normal karyotypes. The
subsequent high-resolution array CGH analysis excluded
the presence in the proband of rare CNVs spanning the
translocation bkp chromosomal bands or localized else-
where in the genome.
As we hypothesized that the rearrangement was the
main cause of the proband’s phenotype, we refined the
bkps by FISH mapping. The chromosome 2 bkp was
mapped at 2p16.1 (Figure 1a), within the region spanned
by probe CTD-2562H20, and refined by CTD-2314I21
(GenBank accession number AC010479.5) (Figure 1b),
whereas the chromosome 8 bkp was identified by the
clone CTD-2176M10 (chr8:116,948,460-117,023,439) at
8q23.3 (Figure 1a,c). Therefore, based on BAC FISH
data, the der(2) and der(8) bkps were mapped within a re-
gion of about 39 kb (chr2:59548766–59587488) and 7.5 kb
(chr8:116978981–116986481), respectively (Figure 1e,f).
The location of the 2p16.1 bkp was further narrowed
down using three contiguous overlapping 15-kb LR-PCR
products as FISH probes (LRP I, II, III) (Figure 1e). The
LRP II produced weak but clear signals on both derivative
chromosomes that were more intense on der(2), sug-
gesting that the bkp was localized within the telomeric
7.5-kb fragment of LRP II target region (chr2:59563376–
59570875) (Figure 1d,e).
The breakpoint junction fragments were then amplified
and sequenced. Sequence alignments showed on der(2)
the loss of two AA bases at position g.59,567,711_
59,567,712, and the duplication of the ATAAGC hexamer
at position g.59,567,716_59,567,721 (Figure 2a). Similarly,
on der(8) a 2-bp GT deletion at position g.116,981,668_
116,981,669, where the missing T is highly conserved [20],
was detected as well as a de novo 4 bp TATG insertion at
position g.116,981,668_116,981,671 (Figure 2b), indicating
that the rearrangement is not completely balanced.
The 8q23.3 breakpoint was precisely located at pos-
ition g.116,981,667_116,981,668 within the IVS10 ofthe long intergenic non-coding RNA (lincRNA) 536
(LINC00536, chr8:116,962,736-117,337,297), at ap-
proximately 300 kb from the TRPS1 5′ end (Figure 2c
and Additional file 5: Figure S2B). The 2p16.1 break-
point was localized at position g.59,567,710_59,567,711
within a 418-bp LINE sequence type 2 (L2a, chr2:59,567,
631-59,568,048) (Additional file 5: Figure S2A). This bkp
is flanked distally, at 1.1 Mb, by the FANCL (Fanconi
anemia, complementation group L) gene, and proximally,
at 1.1 Mb, by the BCL11A (B-cell CLL/lymphoma 11A)
gene. In addition, about 25 kb distally to the der(2) bkp,
we noticed the presence of the conserved non-coding
element (CNE) (VISTA enhancer element hs836 at pos-
ition chr2:59,540,641-59,541,193). Notably, this VISTA
CNE showed a specific expression pattern in transgenic
mouse embryos, demonstrating its activity in facial
mesenchyme development (http://enhancer.lbl.gov/cgi-bin/
imagedb3.pl?form=presentation&show=1&experiment_id=
element_836&organism_id=1). As a result of the transloca-
tion, the enhancer sequence has been relocated to a new
position, at approximately 325 kb from the TRPS1 5′ end
(Figure 2c).
Additional mutations within TRPS1 were excluded in
the proband by sequence analysis.
Discussion
We have herein described a proband with an unusual
presentation of TRPS I, who was found to carry a de
novo reciprocal translocation involving the 2p16.1 and
8q23.3 chromosomal bands. The proband represents an
atypical case as she does not bear a microdeletion
involving TRPS1 or a mutation in the gene coding
sequence, and characterisation of her translocation bkps
excluded the disruption of the TRPS1 gene. The sequence
analysis of the bkp junction fragments, however, precisely
located the 8q23.3 bkp on chromosome der(8) at appro-
ximately 300 kb from the TRPS1 5′ end, thus pointing to
TRPS1 as the gene responsible for the proband’s TRPS I
phenotype. In addition, nucleotide base pair additions and
deletions were detected, thus indicating that the transloca-
tion was likely mediated by the Non-Homologous End
Joining (NHEJ) mechanism [21].
As previously reported in a t(8;13)(q23.3;q21.31) familial
translocation co-segregating with TRPS I [15], in the
present subject neither bkp occurs within a coding region.
Figure 1 (See legend on next page.)
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Figure 1 Mapping of the breakpoint by FISH analysis. (a) Ideograms illustrating the derivative chromosomes involved in the t(2;8)(p16.1;
q23.3)dn, and the normal homologous chromosomes. (b) FISH with BAC clone CTD-2314I21, which spans the translocation bkp at 2p16.1, yields
hybridisation signals of equal intensity on der(2) and der(8) chromosomes. (c) FISH with BAC clone CTD-2176M10, which spans the translocation
bkp at 8q23.3, produces signals of comparable intensity on both derivative chromosomes. (d) FISH with long-range probe (LRP) II, which spans
the translocation bkp at 2p16.1, shows a more intense signal on der(2) than on der(8). (e and f) Physical map of the genomic regions containing
(e) the 2p16.1 bkp and (f) the 8q23.3 bkp, which includes the BAC clones and LRPs used for the FISH analysis. The probes mapping at chromosome
2 (e) and chromosome 8 (f), which show a hybridization signal on der(2), are indicated in grey, whereas those hybridizing on der(8) in light grey. The
probes spanning the bkp regions are indicated by striped black rectangular shapes, the known UCSC genes are shown in black, and the LINC00536 in
light grey (human genome assembly GRCh37/hg19).
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positions of gene regulatory elements with respect to their
original gene targets. We suggest that the disruption and
the possible removal of TRPS1 cis regulatory elements,
such as the LINC00536, might be causative, consistent
with the previous hypotheses in a few reported patients
[12-15]. To date, neither the precise biological function
nor the target gene/s of LINC00536 are known. However,
as lincRNAs are key regulators of diverse cellular pro-
cesses [22], we hypothesize that LINC00536 disruption
might have contributed to the onset of the proband’s clin-
ical phenotype. Interestingly, the 8q23.3 bkp likely inter-
rupts a putative enhancer region [23,24] (Additional file 5:
Figure S2B), and maps within a genomic region where
DNA sequences interacting with transcription factors,
identified by ChIP-seq experiments, have been localized
[25,26] (Additional file 5: Figure S2B).
Notably, the 2p16.1 bkp was positioned at approxi-
mately 25 kb proximal to the conserved VISTA enhancer
element hs836, whose activity in facial mesenchyme devel-
opment has been substantiated by gene reporter assays in
mouse embryos [27]. Similarly to what recently reported
by David et al. [15], in the present subject the enhancer
element was relocated by the translocation in the vicinity
of the TRPS1 5′ end, thus suggesting a possible “enhancer
adoption”, a mechanism recently described by Lettice
et al. [28], which might have perturbed TRPS1 expression
in the facial region during embryonic development. In
agreement with this hypothesis, David et al. [15] detected
an apparently TRPS1 overexpression in the translocation
carriers compared with controls.
There are many potential consequences resulting from
chromosomal rearrangements that could lead to position
effects and thus cause human disease. These include the
moving away of an enhancer or a locus control region
from its gene, the juxtaposition of a gene with a regulatory
element from another gene, and the removal of a bound-
ary element or a long-range insulator [28,29]. On this
basis, the unique reshaping of regulatory elements occur-
ring in the proband could have deregulated the expression
of TRPS1, thus leading to the observed clinical phenotype.
However, we could not demonstrate any alteration in
TRPS1 expression as preliminary TRPS1 gene expres-
sion assays, performed from the proband’s peripheralblood, gave inconclusive results due to very different
TRPS1 expression levels found in controls (Additional
file 6: Figure S3).
The peculiar chromosome rearrangement herein de-
scribed could also explain the differences of both the
craniofacial and skeletal abnormalities of our proband
from those normally found in TRPS patients. Indeed,
important skeletal features of TRPS I such as short stat-
ure, brachydactyly, and the pathognomonic abnormality
of cone-shaped epiphyses were not observed (Additional
file 1: Figure S1). In addition, the proband exhibited the
main TRPS facial dysmorphism as well as bone anomalies
from early infancy; but these were so severe as to require
plastic surgery. Such severe abnormalities, possibly ac-
counted for by significant TRPS1 deregulation in the facial
mesenchyme during development, are not frequently
associated with TRPS. The proband also displayed an
important scoliosis and alopecia universalis, clinical find-
ings that are markedly more severe than those normally
observed in TRPS patients.
Genotype-phenotype correlations were hard to assess
for a few clinical signs, namely minor mental impairment,
diabetes and a mild clinical presentation of connective
tissue disorder (mild joint laxity, severe astigmatism, renal
ptosis, and uterine prolapses). These symptoms may be
caused by mutations of unknown genes, although a con-
tribution of the chromosomal rearrangement in de-
regulating breakpoint-neighbouring genes cannot be
ruled out. Similarly, we cannot exclude the possible
influence of the translocation, via altered gene expression,
on the development of breast cancer. Indeed, TRPS1 gene
overexpression in more than 90% of breast cancers has
been reported [30].
Conclusions
To conclude, this case report, presenting a new case
of association of TRPS I-like phenotype with a recip-
rocal chromosomal translocation which does not disrupt
the TRPS1 coding sequence, increases the number of
TRPS patients whose pathologic phenotype is caused by a
functional disturbance of TRPS1. The clinical and
genetic characterisation of the present subject allowed
us to make a genetic diagnosis in the context of a
known syndrome, contributing to expand the TRPS
Figure 2 Gel electrophoresis of der(2) and der(8) junction fragments, and bkp sequence alignments. (left side) The der(2) (a) and the
der(8) (b) bkp junction fragments were amplified with the primer pairs AF130342-1RW/AC007131-4RW, and AF130342-3FW/AC007131-5FW,
respectively, producing a ~700 and ~600 bp fragments. (right side) Electropherograms of der(2) (a) and der(8) (b) bkp junction fragments are
shown with the respective alignments against the reference sequence. Positions of the bkps at DNA sequence level are indicated (human genome
assembly GRCh37/hg19). Chromosome 8 sequence is in green; sequence related to chromosome 2 in blue; bases lost upon rearrangement in black;
bases inserted de novo in red. The triple-tandem repeats of the ATAAGC de novo acquired hexamer are underlined with a solid line. The GenBank
accession numbers of the submitted der(2) and der(8) junction fragment sequences are KJ561173 and KJ561174, respectively. (c) Ideogram
of chromosome der(8), showing the relocation of the conserved non-coding element (CNE) VISTA enhancer hs836 at an approximate
distance of 325 kb from the TRPS1 5′ region as a result of the translocation. The image is a modification of a version obtained from the
UCSC Genome Browser [17].
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a further comprehension of the complex transcrip-
tional regulation of developmental genes such as TRPS1.
The identification and mapping at nucleotide level ofnovel genomic alterations in TRPS patients will be
necessary to better understand the pathogenesis of
Trichorhinophalangeal syndrome and the regulation
of TRPS1.
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Written informed consent was obtained from the proband
for publication of this Case Report and any accompanying
images. A copy of the written consent is available for
review by the Editor of this journal.
Additional files
Additional file 1: Figure S1. Radiograph of proband’s hands.
Radiograph of left and right hand, which lacks the pathognomonic TRPS
abnormality of cone-shaped epiphyses.
Additional file 2: Table S1. List of primers used to amplify Long-range
PCR fragments on chromosome 2.
Additional file 3: Table S2. List of primers used for amplification of
chromosome der(2) and der(8) junction fragments.
Additional file 4: Table S3. List of primers and amplification conditions
used to perform TRPS1 mutational screening.
Additional file 5: Figure S2. In silico analysis of the genomic regions
containing the translocation bkps. In silico analysis of the genomic
regions containing the 2p16.1 and 8q23.3 bkps. (a) The 2p16.1 bkp
interrupts the repeat element L2a (red arrow) corresponding to a LINE
sequence, and is localised approximately 25 kb from the conserved
non-coding element (CNE) VISTA enhancer hs836. (b) The 8q23.3 bkp
interrupts the lincRNA LINC00536 as well as a putative enhancer region
(in orange), and is located in a region with numerous predicted regulatory
sequences identified by ChIP-Seq experiments (in dark grey). The coloured
bars represent the putative regulatory sequences identified by a probabilistic
Hidden Markov Model (HMM) applied to HMEC cells (Human Embryonic
Stem Cell). The image is a modification of a version obtained from the
UCSC Genome Browser (human genome assembly GRCh37/hg19) [17].
Additional file 6: Figure S3. Reverse transcription quantitative PCR
(RT-qPCR) expression analysis of TRPS1. RT-qPCR expression analysis of
TRPS1. (a) Relative expression level of the TRPS1 transcript in blood
lymphocytes of the proband compared to 10 controls from normal
individuals, by using TaqMan gene expression assays. The amounts of
TRPS1 mRNA (TaqMan assay ID Hs00936363_m1) were calculated using
the 2-ΔΔCt method and expression values were normalised to the
internal control gene GAPDH (TaqMan assay ID Hs99999905_m1) (b)
Similar results were obtained by using the TBP housekeeping gene
(TaqMan assay ID Hs99999910_m1) The expected ΔΔCt ratio is ≅1 when
both alleles are expressed, and 0.5 when only one allele is expressed.
x-axis: a dark grey bar indicates the proband (PB), whereas light grey bars
indicate controls (C1–C10). y-axis: average of three recorded expression
levels for each sample; the proband’s value was set to 1. Statistical
analysis was performed by two-tailed Student’s t test and significance
was considered at P < 0.01.
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